News Releases Year None20242023202220212020201920182017 NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference Aug 29, 2019 NuCana to Participate in Citi’s 14th Annual Biotech Conference Aug 27, 2019 NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update Aug 21, 2019 Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis Aug 20, 2019 NuCana Announces First Patients Dosed in Phase I Study of NUC-7738 Jul 17, 2019 NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer Jun 12, 2019 NuCana to Present at the Jefferies 2019 Healthcare Conference May 30, 2019 NuCana Reports First Quarter 2019 Financial Results and Provides Business Update May 14, 2019 NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference Apr 02, 2019 NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update Mar 07, 2019 Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Page 9 Current page 10 Page 11 Page 12 Page 13 Next page next › Last page last »
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis Aug 20, 2019
NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer Jun 12, 2019
NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update Mar 07, 2019